Effective combination of ET-743 and doxorubicin in sarcoma: Preclinical studies

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 2, 2003, Pages 131-138

  Meco, Daniela ^a   Colombo, Tina ^b   Ubezio, Paolo ^b   Zucchetti, Massimo ^b   Zaffaroni, Marco ^b   Riccardi, Anna ^a   Faircloth, Glynn ^b,c   Jose, Jimeno ^d   D'Incalci, Maurizio ^b   Riccardi, Riccardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Ist Ric Farmacologiche Mario Negri ^*  (Italy)

^c PharmaMar USA Inc   (United States)

^d PHARMAMAR S A   (Spain)

Author keywords

Combination; Doxorubicin; ET 743; Sarcoma

Indexed keywords

DOXORUBICIN; TRABECTEDIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPSY; CANCER COMBINATION CHEMOTHERAPY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; FIBROSARCOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG WEIGHT; MALE; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; DIOXOLES; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; ISOQUINOLINES; MICE; MICE, INBRED C3H; MICE, NUDE; NEOPLASM TRANSPLANTATION; RHABDOMYOSARCOMA; TETRAHYDROISOQUINOLINES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0042878545     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0636-6     Document Type: Article

References (28)

1. Berembaum MC (1985) The expected effect of the combination of agents: the general solution. J Theor Biol 114:413-431
2. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70:73-80
3. Colombo N, Capri G, Bauer J, Noberasco C, De Braud F, Grasselli G, Jimeno J, Ruiz A, Corradino I, Marsoni S, Sessa C (2001) Phase II and pharmacokinetics study of 3 hour infusion of ET-743 I ovarian cancer patients failing platinum-taxanes (abstract). Proc ASCO 21:880
4. Colombo T, Parisi I, Zucchetti M, Sessa C, Goldhirsch A, D'Incalci M (1999) Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol 10:391-395
5. Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M (2001) Unique pattern of ET-743 Activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92:583-588
6. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M, Cvitkovic E (2001) Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patient-s - preliminary evidence of activity. J Clin Oncol 19:1248-1255
7. Demetri GD, Seiden M, Garcia-Carbonero R, Supko J, Harmon D, Goss G, Robinson L, Merrian P, Waxman A, Quigley MT, Jimeno J, Ryan DP (2000) Ecteinascidin (ET-743) shows promising activity in distinct populations of sarcoma patients: summary of 3 US-based phase II trials. Proc ASCO 19:553
8. Erba E, Bergamaschi D, Bassano L, Ronzoni S, Di Liberti G, Muradore I, Vignati S, Faircloth G, Jimeno J, D'Incalci M (2000) Isolation and characterization of an IGRO-1 human ovarian cancer cell line made resistant to ecteinascidin-743 (ET-743). Br J Cancer 82:1732-1739
9. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW (2002) Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 15:3377-3381
10. Giavazzi R, Scholar E, Hart IR (1983) Isolation and preliminary characterization of an Adriamycin-resistant murine fibrosarcoma cell line. Cancer Res 43:2216-2222
11. Giavazzi R, Kartner N, Hart IR (1984) Expression of cell surface P-glycoprotein by an adriamycin-resistant murine fibrosarcoma. Cancer Chemother Pharmacol 13:145-147
12. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT (1999) High antitumor activity of ET-743 against human tumor xenografts from melanoma, non small-cell lung and ovarian cancer. Ann Oncol 10:1233-1240
13. Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clark G, Von Hoff DD (1988) In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9:981-987
14. Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci U S A 97:6775-6779
15. Li WW, Takahashi N, Jhanwar S, Cordon-Cardo C, Elisseyeff J, Jimeno J, Faircloth G, Bertino JR (2001) Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 7:2908-2911
16. Minuzzo M, Marchini S, Broggini M, Fircloth G, D'Incalci, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A 97:6780-6784
17. More BM, Seaman FC, Hurley LH (1997) NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 119:5475-5476
18. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin-743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303
19. Rosing H, Hillebrand MJ, Jimeno JM, Gomez A, Floriano P, Faircloth G, Henrar RE, Vermorken JB, Cvitkovic E, Bult A, Beijnen JH (1998) Quantitative determination of ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Mass Spectrom 33:1134-1140
20. Speth PA, van Hoesel QG, Haanen C (1988) Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 15:15-31
21. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR (2001) Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 7:3251-3257
22. Takebayashi Y, Pourquier P, Yoshida A, Kohlhagen G, Pommier Y (1999) Poisoning of human DNA topoisomerase I by ecteinascidin-743, an anticancer drug that selectively alkylates DNA in the minor groove. Proc Natl Acad Sci U S A 96:7196-7201
23. Valoti G, Nicoletti MI, Pellegrino A, Jimeno I.M, Hendriks H, D'Incalci M, Faircloth G, Giavazzi R (1998) Ecteinascidin-743, a new marine natural product with potent antitumour activity on human ovarian carcinoma xenografts. Clin Cancer Res 4:1977-1983
24. van Kesteren C, Cvitkovic E, Taamma A, Lopez-Lazaro L, Jimeno JM, Guzman C, Matht RA, Schellens JH, Misset JL, Brain E, Hillebrand MJ, Rosing H, Beijnen JH (2000) Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 6:4725-4732
25. van Kesteren C, Twelves C, Bowman A, Hoekman K, Lopez-Lazaro L, Jimeno J, Guzman C, Mathot RA, Simpson A, Vermorken JB, Smyth J, Schellens JH, Hillebrand MJ, Rosing H, Beijnen JH (2002) Clinical pharmacology of the novel marine-derived anticancer agent ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 13:381-393
26. Yovine A, Riofrio M, Brain E, Blay JY, Kahatt C, Delaloge S, Bautier L, Coffu P, Jimeno J, Cvitkovic E, Misset JL (2001) Ecteinascidin (743) given as a 24 hours (H) intravenous continuous infusion (IVCI) every 3 weeks: results of a phase II trial in patients (pts) with pretreated soft tissue sarcomas (PSTS). Proc Am Soc Clin Oncol 20:36A
27. Zelek L, Yovine A, Brain E, Tuepin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Cvitkovic E, Misset JL (2000) Preliminary results of phase II study of ecteinascidin-743 (ET-743) with the 24 hour (H) continuous infusion (CI) Q3weeks schedule in pretreated advanced/metastatic breast cancer (A/MBC) patients (Pts) (abstract 212). Proceedings 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy. Clin Cancer Res [Suppl] 6:85
28. Zewail-Foote M, Li VS, Kohn H, Bearss D, Guzman M, Hurley LH (2001) The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent. Chem Biol 8:1033-1049